Journal retracts vaping cancer study amid major flaws

The retraction of a vaping-related paper in Journal of Cancer Policy, published by Elsevier, has renewed scrutiny over the quality and interpretation of research on e-cigarettes, with implications for public health messaging and regulatory debate.

The journal has withdrawn a systematic review examining vaping as a cancer risk factor after identifying what it described as “substantial concerns” about the study’s methodological integrity, accuracy and scientific validity. According to the official retraction notice, a detailed evaluation uncovered “multiple serious flaws that materially affect the reliability of the findings and conclusions.”

Editors highlighted a range of issues, including undisclosed deviations from the study’s original protocol, inconsistencies in the reported search strategy, and the misclassification of study designs. The review also included a previously retracted paper while presenting internal contradictions in study counts, sample sizes and outcome data. The notice concluded that the paper’s findings were not supported by the evidence presented, undermining confidence in its conclusions.

The authors, affiliated to various institutions in Natal, Brazil, did not respond to requests for clarification within the allotted timeframe, leading the editor-in-chief to determine that the article failed to meet the journal’s standards for scientific accuracy and reliability.

The development follows a separate high-profile retraction earlier this year by open access publisher MDPI, which withdrew a controversial study claiming that e-cigarette users faced a higher risk of early stroke than traditional smokers. That paper was also pulled after concerns over major analytical errors that could not be resolved.

Campaign group Smoke Free Sweden said the latest episode highlights a growing problem in the global tobacco debate: the rapid spread of unreliable claims about safer nicotine alternatives.

“This case is a stark reminder that misinformation can travel far faster than scientific corrections,” said Dr Delon Human, leader of Smoke Free Sweden. “When flawed research enters the public debate it can distort policy discussions and mislead smokers who are looking for better options.”

Dr Human warned that inaccurate claims about reduced-risk products risk undermining efforts to move smokers away from combustible cigarettes, which remain the leading cause of tobacco-related disease.

“Millions of smokers need clear, accurate information about the relative risks of nicotine products,” he said. “Poorly conducted research can delay harm-reduction strategies that save lives.”

Alongside these retractions, a newly published academic commentary has raised further questions about how vaping evidence is interpreted. Researchers identified a pattern in systematic reviews of e-cigarettes for smoking cessation, where statistically significant benefits are reported in the data but not reflected in the conclusions.

The authors describe this phenomenon as “reverse spin bias”, referring to instances where positive findings are acknowledged but subsequently downplayed or dismissed. They argue that this may contribute to confusion among policymakers and healthcare professionals regarding the role of vaping in harm reduction.

Industry stakeholders have repeatedly warned that flawed analyses and inconsistent interpretation risk skewing public perception and influencing policy decisions. The UK Vaping Industry Association has recently launched a new expert panel, VapeVerify, to scrutinise vaping research and challenge what they describe as “bad science”.

The initiative will assess issues such as poor methodology, misinterpretation of data and lack of transparency, with the aim of ensuring policy and public debate are shaped by robust evidence.